Skip to main content
Download PDF
  • Research article
  • Open access
  • Published:

Stroke risk after transient ischemic attack in a Norwegian prospective cohort

BMC Neurology volume 19, Article number: 2 (2019) Cite this article

Abstract

Background

Transient ischemic attack (TIA) is a risk factor of stroke. Modern treatment regimens and changing risk factors in the population justify new estimates of stroke risk after TIA, and evaluation of the recommended ABCD2 stroke risk score.

Methods

From October, 2012, to July, 2014, we performed a prospective, multicenter study in Central Norway, enrolling patients with a TIA within the previous 2 weeks. Our aim was to assess stroke risk at 1 week, 3 months and 1 year after TIA, and to determine the predictive value of the dichotomized ABCD2 score (0–3 vs 4–7) at each time point. We used data obtained by telephone follow-up and registry data from the Norwegian Stroke Register.

Results

Five hundred and seventy-seven patients with TIA were enrolled of which 85% were examined by a stroke specialist within 24 h after symptom onset. The cumulative incidence of stroke within 1 week, 3 months and 1 year of TIA was 0.9% (95% CI, 0.37–2.0), 3.3% (95% CI, 2.1–5.1) and 5.4% (95% CI, 3.9–7.6), respectively. The accuracy of the ABCD2 score provided by c-statistics at 7 days, 3 months and 1 year was 0.62 (95% CI, 0.39–0.85), 0.62 (95% CI, 0.51–0.74) and 0.64 (95% CI, 0.54–0.75), respectively.

Conclusions

We found a lower stroke risk after TIA than reported in earlier studies. The ABCD2 score did not reliably discriminate between low and high risk patients, suggesting that it may be less useful in populations with a low risk of stroke after TIA.

Trial registration

Unique identifier: NCT02038725 (retrospectively registered, January 16, 2014).

Peer Review reports

Background

Stroke is a major cause of disability and death worldwide. Transient ischemic attack (TIA) has the same etiology as stroke, and patients with a TIA have been shown to be at high risk of a subsequent stroke although the stroke risk varies in different studies depending on study population and methodology [1, 2].

Several clinical risk scores have been developed to identify TIA patients with high and low early stroke risk in order to triage the patients in primary and secondary care. The ABCD2 score from 2007 has achieved particular prominence [3]. The score is based on clinical information that is easily obtained, consisting of age, blood pressure, type of symptoms, duration of symptoms and presence of diabetes (Table 1). Validations of the ABCD2 score have given conflicting results regarding accuracy for both short and long term stroke prediction [4, 5]. However, it remains the most widely used risk score in TIA patients, and several guidelines recommend that patients with a high ABCD2 score (4–7), indicating high risk of stroke, should receive specialist assessment within 24 h after the onset of TIA, while for patients with a low score (0–3) specialist assessment within a few days after TIA is considered sufficient [6,7,8].

Table 1 ABCD2 score
Full size table

Prospective cohort studies on stroke risk after TIA stratified by the ABCD2 score, have not been performed in Scandinavia. Since stroke patients in Norway and other Scandinavian countries differ from stroke populations in many other countries by having lower post-stroke mortality [9], it is timely to assess if TIA patients also differ when it comes to stroke risk and survival. Moreover, modern treatment regimens and alteration in risk factors in the population make it necessary to estimate the risk of stroke after TIA and evaluate whether the recommended ABCD2 risk score is still useful in identifying TIA patients at the highest stroke risk. The primary aim was to establish a large prospective cohort of TIA patients to find the cumulative stroke risk within 1 week, 3 months and 1 year after TIA. Secondary, we evaluated the predictive value of the dichotomized ABCD2 score 0–3/4–7. Additionally, 1 year follow-up data on endarterectomy for symptomatic carotid stenosis, and case fatality, was recorded.

Methods

Study design and patient selection

In a prospective, multicenter study, named MIDNOR TIA, TIA patients were consecutively enrolled from October, 2012, to July, 2014. All eight hospitals in the geographical and administrative region of Central Norway recruited patients, of which seven were community hospitals and one a university hospital. Only the university hospital had an out-patient service for acute TIA diagnostics and treatment. TIA patients eligible for enrollment were residents of Central Norway aged 18 to 90 years, they were evaluated by a stroke specialist within 2 weeks of their TIA, and living at home with a modified Rankin Scale of ≤3.

Data collection and follow-up

Stroke physicians performed inclusion according to eligibility criteria after in-person assessment on the hospital ward, or in a few cases in the outpatient clinic, and then recorded the ABCD2 score in standardized paper forms that explicitly listed each component of the score. A standardized diagnostic work-up contained as a minimum a thorough patient history, a physical examination, blood tests, ECG, a brain MRI or CT, and carotid Doppler ultrasound or CT angiography. Trained research nurses appointed at each center prospectively registered detailed baseline data using standardized web-based case report forms. Subsequent stroke (ischemic and hemorrhagic) within 1 week, 3 months and 1 year after the index TIA, was recorded by telephone follow-up at each time point. Additionally, all registered strokes were confirmed by using data from the Norwegian Stroke Register, which is the national quality registry for stroke care established by law. Data from the Norwegian Cardiovascular Disease Registry was used for registering deaths and carotid surgery in the 1 year follow-up period.

Definitions

TIA was defined as an acute loss of focal cerebral or ocular function lasting less than 24 h according to the diagnostic criteria from the World Health Organization (WHO) [10]. The TIA leading the patient to seek medical help, was defined as the index TIA. The WHO criteria were also used for stroke [11].

The blood pressure measurement used for the ABCD2 assignment was the first ever recorded after the onset of the TIA, and in most cases it was recorded in the emergency department. Carotid stenosis was defined as a ≥ 50% narrowing of the symptomatic internal carotid artery on carotid imaging, and the diagnosis of atrial fibrillation was based on at least one confirmative ECG prior to or during the investigation.

Clinical management

The clinical management followed the current treatment guidelines for TIA [12]. Patients were treated with an antiplatelet agent, mainly aspirin, as soon as possible after the TIA. Hypercholesterolemia, hypertension, atrial fibrillation and diabetes were treated according to current guidelines, supplemented with lifestyle advices. Patients with symptomatic, significant carotid stenosis were in the absence of contraindications treated with endarterectomy. Follow-up of secondary prevention was performed by the patients’ general practitioners.

Statistical analysis

In a large, previous study [3] of TIA patients (n = 4809), an ABCD2 score of 0–3 (1628/4809–34%) gave a 1 week stroke risk of < 1% and a score of 4–7 (3181/4809–66%) gave a stroke risk of > 5%. Based on these results, we calculated a requirement of 564 patients in the present study (significance level 0.05 and power 80%).

Kaplan-Meier analysis was used to determine the cumulative incidence of stroke, and the log rank test was used to assess for statistical differences in stroke-free survival between the ABCD2 groups. Deaths from other causes than stroke were treated as censoring events. The predictive ability of the ABCD2 score was quantified by the areas under the curve (AUC) of a receiver operating characteristics curve (ROC). Confidence intervals (CI) for binomial proportions were calculated using the Wilson score method. We performed Cox proportional hazards regression analysis to calculate hazard ratios (HRs), using the low-risk ABCD2 group as the reference category.

Descriptive statistics for continuous variables are given as means with standard deviations (SD), and for categorical variables as frequencies and percentages. Statistical analyses were performed using IBM SPSS Statistics (version 23).

Results

Originally 591 patients were enrolled, but 7 patients later withdrew their consent. Another 7 patients were excluded, either because symptoms lasted for more than 24 h (n = 1), or because the diagnostic work-up excluded the diagnosis of TIA (n = 6). Thus, the final study population included 577 patients.

Table 2 summarizes the baseline characteristics, the clinical features and the main investigations of the study population. The mean (SD) age of the patients was 71.5 years (11.0). Four hundred and eighty-nine patients (84.7%) were above 60 years of age and 56.7% were male. A total of 467 subjects (82.5%) experienced their first ever TIA. Four hundred and ninety-one patients (85.4%) were examined by a stroke specialist within 24 h and 525 patients (91%) within 48 h after symptom onset. Only 27 (4.7%) were evaluated at the outpatient clinic, whereas the majority of patients were hospitalized. Median length of hospital stay was 2 days. Speech difficulties, motor weakness and sensory deficits were the most commonly reported symptoms. Forty-eight of 520 (9.2%) patients who had intra- and extracranial imaging performed had a symptomatic carotid stenosis. All patients were examined with brain imaging, either with a CT scan (97.7%) or a diffusion-weighted MRI (DWI-MRI) (62.6%), or both, and all patients were evaluated with either ECG or 24-h Holter ECG, or both.

Table 2 Baseline characteristics, clinical features and main investigations of the study population
Full size table

Stroke risk and case fatality

Five patients had a stroke within 1 week, 19 patients within 3 months, and 31 patients within 1 year, corresponding to a cumulative incidence of stroke of 0.9, 3.3 and 5.4%, respectively. Twenty-seven (87.1%) of the 31 recurring strokes within 1 year were ischemic strokes, and 4 were intracranial hemorrhages.

All strokes within 1 week occurred within the first 2 days after the TIA. The 5 patients experiencing a stroke within 1 week had ABCD2 scores of 3, 4, 4, 6 and 6, respectively (mean score 4.6). One of them had atrial fibrillation and one had a symptomatic carotid stenosis, both of these had ABCD2 score of 6. Of all included patients, 9.6% versus 10.2% had carotid stenosis and 11.7% versus 14.8% had atrial fibrillation in the low and high risk group, respectively.

In all, 26 of 48 patients with significant, symptomatic carotid stenosis underwent carotid endarterectomy. During the entire follow-up period of 1 year 10 (1.7%) of the patients died and three of them by hemorrhagic strokes.

ABCD2 score and stroke risk

In all, 64.3% (n = 371) had a high risk ABCD2 score 4–7. The median ABCD2 score was 4 (IQR 3–5). Figure 1 shows the Kaplan-Meier curves of patients surviving free from stroke from the time of presenting TIA within 1 week, 3 months and 1 year, stratified according to ABCD2 score 0–3 and 4–7. The low risk group shows a higher probability of stroke free survival than the high risk group, although the difference is not statistically significant (p = 0.46 at 1 week, p = 0.18 at 3 months, p = 0.051 at 1 year, log rank test).

Fig. 1
figure 1

Kaplan-Meier plots of patients surviving free from stroke from time of presenting TIA within 1 week (a), 3 months (b) and 1 year (c) stratified according to ABCD2 score 0–3 and 4–7. Log rank tests for differences between the groups

Full size image

The distribution of the ABCD2 score with the corresponding stroke rates at each time point is shown in Table 3. In patients with ABCD2 score 0 or 1 no strokes occurred at any time point, and for score 2–3 only one stroke within a week. However 19.4% (n = 6) of all strokes for the whole period occurred in patients with ABCD2 score 2–3. The risk of stroke tended to increase with a higher ABCD2 score, with the risk at 1 year ranging from 0% (score of 0 and 1) to 13.2 and 10.5% (score of 6 and 7, respectively).

Table 3 The 1 week, 3 months and 1 Year Risks of Stroke According to Each Stratum of the ABCD2 Score and Dichotomized Score, with Corresponding AUC Levels for each Time Point
Full size table

The area under the ROC curve was 0.62 (95% CI = 0.39 to 0.85, p = 0.36) at 1 week, 0.62 (95% CI = 0.51 to 0.74, p = 0.065) at 3 months, and 0.64 (95% CI = 0.54 to 0.75, p = 0,008) at 1 year (Fig. 2). A cox regression analysis comparing high ABCD2 score (4–7) with low (reference) score (0–3) showed hazard ratios of 2.22 (95% CI, 0.25 to 19.88, p = 0.48), 2.11 (95% CI, 0.7 to 6.35, p = 0.19) and 2.37 (95% CI, 0.97 to 5.77, p = 0.058) at 1 week, 3 months and 1 year, respectively.

Fig. 2
figure 2

Receiver operating characteristics curves (ROC) for predictive value of ABCD2 score within 1 week (a), 3 months (b) and 1 year (c). AUC = Area Under the Curve)

Full size image

Discussion

Stroke risk

We found a low stroke risk after TIA in our study. Both early and late stroke risks were lower than reported in cohorts used to develop and validate the ABCD2 score [3], and in several previous TIA cohorts. The pooled stroke risk at 7 days in a meta-analysis published in 2007 reporting from 17 TIA studies performed between 1981 and 2007 was 5.2% [1], 5-fold the risk we found in our study. In the Oxfordshire study the 1 year stroke risk was 11.6% [13], more than two times the stroke risk we found within 1 year. However, the estimated stroke risks in our cohort are in line with the findings in more recent studies [2, 14], including studies evaluating the effect of rapid assessment and initiation of preventive treatment for TIA patients [15,16,17]. This trend towards a lower stroke recurrence probably reflects both a more rapid evaluation by stroke specialists and improved treatment and secondary prevention strategies implemented for TIA patients during the recent years. In Scandinavia these findings parallel the improved outcome for stroke patients [9], reflecting high quality of initial assessment, treatment and follow-up of both stroke and TIA patients. Differences in socioeconomic status, health economics and health care organization between countries might have an influence on the varying stroke risks found in TIA studies. Performing large TIA studies in different countries provides valuable information on the current post-TIA stroke risk.

To what extent the high hospitalization rate in our study contributed to the low stroke risk is unclear. The aim of the present study was not to compare out-patient and in-patient TIA services. However, in the rapid assessment studies, the EXPRESS study [15] and the SOS-TIA study [16], in which patients were assessed and treated in dedicated out-patient TIA clinics, the very low subsequent stroke rates were attributed to the systematized rapid assessment and treatment initiation. Similarly, in our study, the vast majority of patients, regardless of belonging to low risk or high risk group, were evaluated by a specialist shortly after the event (9 of 10 within 24 h). Only 2% of the patients were enrolled between 1 and 2 weeks after the event. In the small number of patients who were enrolled after 24–48 h from symptom onset, there was one stroke. Excluding these patients from the calculations changes the stroke risks only minimally.

Furthermore, a meta-analysis of 12 randomized trials of aspirin versus control in secondary prevention after TIA or ischemic stroke, identified early administration of aspirin as a key intervention [18]. This may be the main contributor to the low event rate of ischemic stroke during the first days after TIA. In the TIA studies of the meta-analysis from 2007 [1], treatment with aspirin varied considerably, ranging between 47 and 90%. In our study 80.2% of the patients were treated with aspirin, either alone (31%), in combination with dipyridamole (43.7%) or in combination with clopidogrel (5.5%). Aspirin is a simple and low-cost treatment that can be initiated urgently after a TIA, independent of the organization of TIA management on an out-patient or in-patient basis. In contrast, the beneficial effect of other initiated treatments, like antihypertensive and lipid-lowering medication, occurs over time. Promising results regarding dual antiplatelet therapy with aspirin and clopidogrel have been found in two recent studies on stroke risk after TIA or minor stroke [19, 20]. The results however were presented after the initiation of our study, and their clinical implementation need to be validated further.

We acknowledge that neurological symptoms in some enrolled patients might have been caused by non-ischemic conditions, causing a weakening of the association between TIA and stroke risk. However, low risk of stroke explained by misclassification is not likely due to inclusion performed by trained stroke physicians with several years of experience with TIA and stroke patients. Secondly, the ABCD2 distribution in our study, with about two thirds of the patients having a high risk score of 4 or more, and a median score of 4, was not towards a lower risk than TIA populations in previous cohorts [3,4,5]. Thirdly, reclassification of DWI-MRI positive TIAs as stroke can potentially reduce the incidence of subsequent stroke in TIA prognostic studies, since the DWI negative TIAs have been shown to have a lower stroke risk than DWI positive TIAs [21]. All physicians involved in study inclusion were informed to use the time-based TIA-definition. Finally, the mean time from onset to hospital admission was only 17 h, which indicates an appropriate follow-up from TIA onset for most patients and thus prevented loss of stroke-events during the first few days when the risk of stroke after TIA is regarded as high [22].

ABCD2 score

In the low risk ABCD2 group there were very few strokes, so a low ABCD2 score still indicates a very low stroke risk. However a new and interesting finding was that patients with a high ABCD2 score also had a low risk of stroke. Although there were approximately twice as many strokes in the high versus the low risk group at each time point, we did not find significant differences in the Kaplan-Meier analysis. The hazard ratios of 2.1 to 2.4 confirm the same trend towards higher stroke occurrence in the high risk group, but again these were non-significant differences. Furthermore ROC analyses showed insufficient discriminating value of the ABCD2 score both when applied 1 week, 3 months and 1 year after stroke.

Only 1 of 206 patients with an ABCD2 score of ≤3 experienced a stroke within 1 week. However, as shown in earlier studies, patients with low ABCD2 score may have underlying severe pathology, like atrial fibrillation and internal carotid stenosis, which underscores benefit from rapid diagnostic evaluation regardless of risk score [16, 23]. In the present study there were no significant differences in the prevalence of carotid stenosis and atrial fibrillation in the low- and high risk group.

Strengths and limitations

The strength of the study is the prospective design with the use of standardized diagnostic criteria. The study was conducted in a well-defined geographical region in close collaboration with all the local hospitals and primary health care system. The high adherence to current guidelines regarding assessment and treatment make it a “real-life” clinical scenario, meaning that these findings can be generalized and applied in a broader health-care setting.

The main limitation of our study is the lack of power caused by the low rate of strokes. With a larger cohort we might have been able to show significant differences between the two risk groups. The power calculation was, however, based on current knowledge of post-TIA stroke risk and cannot be considered a methodological error. The fact that our study is not population-based can imply selection bias, as for instance some very mild or short lasting TIAs might not have come to medical attention, or were treated by the general practitioner without referral to the hospital. It is, however, likely that the majority of these patients constitute a low risk group and would have resulted in an even weaker association between TIA and subsequent stroke if included in the analyses. As in most studies, missing data are unavoidable, but the outcome variables were confirmed by using well-functioning national quality registries, and there were no missing ABCD2 scores.

Conclusions

In our study TIA patients had a very low risk of stroke, indicating that the health services in our region offer TIA patients management of high quality. Urgent assessment and intervention are likely the main reasons for the low stroke risk.

Low ABCD2 score predicted very low risk of stroke. However, patients with a high score also had a low risk of stroke. Due to the low numbers of stroke, the study did not have sufficient power to detect significant differences in stroke risk between patients with high and low ABCD2 score. Our results can still indicate that the ABCD2 score may be less applicable to discriminate between high and low stroke risk groups in populations with a low risk of stroke after TIA. Patients with a low score also can have severe underlying pathology, hence rapid evaluation seems to be the key factor for optimizing the outcome in all TIA patients.

Abbreviations

AUC:

Areas under the curve

CI:

Confidence intervals

DWI:

Diffusion-weighted imaging

HR:

Hazard ratios

IQR:

Interquartile range

ROC:

Receiver operating characteristics curve

TIA:

Transient ischemic attack

References

  1. Giles MF, Rothwell PM. Risk of stroke early after transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol. 2007;6:1063–72.

    Article  Google Scholar 

  2. Amarenco P, Lavallee PC, Labreuche J, et al. One-Year Risk of Stroke after Transient Ischemic Attack or Minor Stroke. New England J Med. 2016;374:1533–42. https://doi.org/10.1056/NEJMoa1412981.

    Article  CAS  Google Scholar 

  3. Johnston SC, Rothwell PM, Nguyen-Huynh MN, et al. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet. 2007;369:283–92. https://doi.org/10.1016/s0140-6736(07)60150-0.

    Article  PubMed  Google Scholar 

  4. Wardlaw JM, Brazzelli M, Chappell FM, et al. ABCD2 score and secondary stroke prevention: meta-analysis and effect per 1,000 patients triaged. Neurology. 2015;85:373–80. https://doi.org/10.1212/wnl.0000000000001780.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Giles MF, Rothwell PM. Systematic review and pooled analysis of published and unpublished validations of the ABCD and ABCD2 transient ischemic attack risk scores. Stroke. 2010;41:667–73. https://doi.org/10.1161/strokeaha.109.571174.

    Article  PubMed  Google Scholar 

  6. Easton JD, Saver JL, Albers GW, et al. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke. 2009;40:2276–93. https://doi.org/10.1161/strokeaha.108.192218.

    Article  PubMed  Google Scholar 

  7. National Collaborating Centre for Chronic C. National Institute for Health and Clinical Excellence: Guidance. In: Stroke: National Clinical Guideline for Diagnosis and Initial Management of Acute Stroke and Transient Ischaemic Attack (TIA). London: Royal College of Physicians (UK) Royal College of Physicians of London; 2008.

    Google Scholar 

  8. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis. 2008;25:457–507. https://doi.org/10.1159/000131083.

  9. OECD. Health at a Glance 2015: OECD Publishing.

  10. Hatano S. Experience from a multicentre stroke register: a preliminary report. Bull World Health Organ. 1976;54:541–53.

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Aho K, Harmsen P, Hatano S, et al. Cerebrovascular disease in the community: results of a WHO collaborative study. Bull World Health Organ. 1980;58:113–30.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Helsedirektoratet. Nasjonal retningslinje for behandling og rehabilitering ved hjerneslag 2010.

    Google Scholar 

  13. Dennis M, Bamford J, Sandercock P, et al. Prognosis of transient ischemic attacks in the Oxfordshire Community Stroke Project. Stroke. 1990;21:848–53.

    Article  CAS  Google Scholar 

  14. Appelros P, Hals Berglund M, Strom JO. Long-Term Risk of Stroke after Transient Ischemic Attack. Cerebrovasc Dis. 2016;43:25–30. https://doi.org/10.1159/000451061.

    Article  PubMed  Google Scholar 

  15. Rothwell PM, Giles MF, Chandratheva A, et al. Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. Lancet. 2007;370:1432–42. https://doi.org/10.1016/s0140-6736(07)61448-2.

    Article  PubMed  Google Scholar 

  16. Lavallée PC, Meseguer E, Abboud H, et al. A transient ischaemic attack clinic with round-the-clock access (SOS-TIA): feasibility and effects. The Lancet Neurology. 2007;6:953–60. https://doi.org/10.1016/S1474-4422(07)70248-X.

    Article  CAS  PubMed  Google Scholar 

  17. Cucchiara BL, Messe SR, Taylor RA, et al. Is the ABCD score useful for risk stratification of patients with acute transient ischemic attack? Stroke. 2006;37:1710–4. https://doi.org/10.1161/01.str.0000227195.46336.93.

    Article  PubMed  Google Scholar 

  18. Rothwell PM, Algra A, Chen Z, et al. Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. Lancet. 2016;388:365–75. https://doi.org/10.1016/s0140-6736(16)30468-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Wang Y, Wang Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013;369:11–9. https://doi.org/10.1056/NEJMoa1215340.

    Article  CAS  PubMed  Google Scholar 

  20. Johnston SC, Easton JD, Farrant M, et al. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. N Engl J Med. 2018;379:215–25. https://doi.org/10.1056/NEJMoa1800410.

    Article  CAS  PubMed  Google Scholar 

  21. Mullen MT, Cucchiara BL. Redefinition of transient ischemic attack improves prognosis of transient ischemic attack and ischemic stroke: an example of the will rogers phenomenon. Stroke. 2011;42:3612–3. https://doi.org/10.1161/strokeaha.111.627877.

    Article  CAS  PubMed  Google Scholar 

  22. Lovett JK, Dennis MS, Sandercock PA, et al. Very early risk of stroke after a first transient ischemic attack. Stroke. 2003;34:e138–40. https://doi.org/10.1161/01.str.0000080935.01264.91.

    Article  CAS  PubMed  Google Scholar 

  23. Amarenco P, Labreuche J, Lavallee PC. Patients with transient ischemic attack with ABCD2 <4 can have similar 90-day stroke risk as patients with transient ischemic attack with ABCD2 >/=4. Stroke. 2012;43:863–5. https://doi.org/10.1161/strokeaha.111.636506.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We thank the patients, study nurses, physicians and other colleagues that participated in the study.

Funding

The MIDNOR TIA study was funded by the Liaison Committee between the Central Norway Regional Health Authority (RHA) and the Norwegian University of Science and Technology (NTNU), and the former Liaison Committee between the Medical Faculty of NTNU and St. Olav’s Hospital, Trondheim University Hospital. The funders had no role in study design, data collection and analysis, or preparation of the manuscript.

Availability of data and materials

Deposition of patient level data in a public repository was not specified in the study protocol, which was approved by the ethics committee before the study began. Patient-level data will be available on request, provided that the Regional Ethics Committee gives approval.

Author information

Authors and Affiliations

  1. Department of Neuromedicine and Movement Science, Faculty of Medicine and Health Sciences, NTNU - Norwegian University of Science and Technology, P.O.Box 8905, N-7491, Trondheim, Norway

    Fredrik Ildstad, Hanne Ellekjær, Geir Bråthen & Bent Indredavik

  2. Department of Medicine, Stroke Unit, Trondheim University Hospital, P.O.Box 3250, N-7006, Trondheim, Norway

    Fredrik Ildstad, Hanne Ellekjær & Bent Indredavik

  3. Department of Cardiology, Trondheim University Hospital, P.O.Box 3250, N-7006, Trondheim, Norway

    Torgeir Wethal

  4. Regional Center for Child and Youth Mental Health and Child Welfare, NTNU, P.O.Box 8905, N-7491, Trondheim, Norway

    Stian Lydersen

  5. Department of Clinical and Molecular Medicine, NTNU, P.O.Box 8905, N-7491, Trondheim, Norway

    Janne Kutschera Sund

  6. Department of Medical Quality Registries, Trondheim University Hospital, P.O.Box 3250, N-7006, Trondheim, Norway

    Hild Fjærtoft

  7. Department of Neurology, Namsos Hospital, P.O.Box 453, N-7801, Namsos, Norway

    Stephan Schüler

  8. Department of Neurology, Levanger Hospital, P.O.Box 333, N-7601, Levanger, Norway

    Jens Wilhelm Horn

  9. Department of Neurology, Trondheim University Hospital, P.O.Box 3250, N-7006, Trondheim, Norway

    Geir Bråthen

  10. Department of Medicine, Kristiansund Hospital, N-6508, Kristiansund, Norway

    Ann-Grete Midtsæther

  11. Department of Neurology, Molde Hospital, N-6412, Molde, Norway

    Åse Hagen Morsund

  12. Department of Medicine, Volda Hospital, P.O.Box 113, N-6103, Volda, Norway

    Marja-Liisa Lillebø

  13. Department of Medicine, Ålesund Hospital, P.O.Box 1600, N-6026, Ålesund, Norway

    Yngve Müller Seljeseth

Authors
  1. Fredrik Ildstad
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hanne Ellekjær
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Torgeir Wethal
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stian Lydersen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Janne Kutschera Sund
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hild Fjærtoft
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Stephan Schüler
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jens Wilhelm Horn
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Geir Bråthen
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ann-Grete Midtsæther
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Åse Hagen Morsund
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Marja-Liisa Lillebø
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Yngve Müller Seljeseth
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Bent Indredavik
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

BI, HE and TW contributed to conception and design of the study. BI and FI were involved in gaining ethical approval. FI performed all analyses after discussions with and statistical input from SL. FI wrote the first draft of the manuscript. SS, JWH, GB, AGM, ÅHM, MLL, YMS, BI, HE and FI were responsible for patient recruitment, assessment and data collection at their respective hospitals. JKS contributed to follow-up of patients. HF was responsible for data from the Norwegian Stroke Register. All authors reviewed and edited the manuscript and approved the final version of the manuscript.

Corresponding author

Correspondence to Fredrik Ildstad.

Ethics declarations

Ethics approval and consent to participate

The study was approved (REC no. 2012/1224) by the Regional Committee of Medical and Health Research Ethics of Møre og Romsdal and Trøndelag, Norway (REC Central, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology). Permission to use data from the Norwegian Cardiovascular Disease Registry, hereunder the Norwegian Stroke Register, was granted by the Norwegian Institute of Public Health. Written informed consent was obtained from all subjects before study inclusion.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ildstad, F., Ellekjær, H., Wethal, T. et al. Stroke risk after transient ischemic attack in a Norwegian prospective cohort. BMC Neurol 19, 2 (2019). https://doi.org/10.1186/s12883-018-1225-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12883-018-1225-y

Keywords

BMC Neurology

ISSN: 1471-2377

Contact us